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Abstract 
Increased International collaborative research activities in poor and low-income countries 
have several unique claims on our attention. First, the idea of involving human beings in 
research, putting forward participants openly to trials presents a novel experiment in which 
various academic disciplines can play in order to enhance fair studies. Second, apart from the 
need to conduct research in medical and health related areas, there have been many ethical 
challenges including the necessity to prevent harm among research participants and to ensure 
that they receive a fair share of benefits from research results. 
Despite existence of ethical guidelines and declarations, potential research participants from 
poor and low-income countries in particular, still risk exploitation due to limited health care 
access, and little awareness of research on human beings. It is, therefore, necessary for us to 
examine the main features of this system, which provides the framework within which 
research activities are done; in order to find out if and how research ethics can be used to 
enhance fair studies.  
This thesis has attempted to provide a careful assessment of current debates on exploitation in 
medical and health related research ethics, with special emphasis on the different revisions of 
the declaration of Helsinki - and other relevant international declarations and ethical 
guidelines through literature analysis; to investigate the concept of exploitation among 
vulnerable groups in poor and low income populations. Empirical case studies including 
informal discussions with existing research ethics committee members were sought from 
Tanzania. 
Analysed literature findings reveal that the concept of exploitation has been expressed in 
various ways. New forms of exploitation in medical and health related research ethics include 
the use of placebo and the modification of the concept of benefit to include forms of benefit 
not directly related to trials under consideration. There are strong urges to abandon the current 
revision of declaration of Helsinki and adopt the Universal Declaration on Bioethics and 
Human Rights (UDBHR), as the viable guideline in medical and health related research 
ethical requirements. The need to establish a coalition between member states regional wise is 
proposed as a desirable option in order to see to it that the UDBHR is implemented. 
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The Concept of Exploitation in Medical and Health Related Research Ethics: Literature 
Analysis 
Background / Summary 
Increased international collaborative research activities in poor and low-income countries 
have several unique claims on our attention. First, the idea of involving human beings in 
research, putting forward participants openly to trials presents a novel experiment in which 
various academic disciplines can play a role in order to enhance fair studies. Second, apart 
from the need to conduct research in medical and health related areas, there are many ethical 
challenges including the necessity to prevent harm among research participants and to ensure 
that they receive a fair share of benefits from research results. Despite the existence of ethical 
guidelines and declarations, potential research participants from poor and low-income 
countries in particular, still risk exploitation due to limited access to health care and little 
awareness of research on human beings. It is, therefore, necessary for us to examine the main 
features of this system, which provides the framework within which research activities are 
done; in order to find out if and how research ethics can be used to enhance fair studies. 
 
This study aims at providing a careful analysis and assessment of current debates on 
exploitation in medical and health related research ethics, with special emphasis on the 
different revisions of the declaration of Helsinki - and other relevant international declarations 
and ethical guidelines. In particular I aim at investigating how the latest revisions of 
international declarations and guidelines in medical and health related research may have 
diluted the ethical requirements in terms of opening up a "loop hole" for exploitation of 
vulnerable groups in poor and low income countries. 
Controversial issues include: The revision of the use of placebo and the modification of the 
concept of benefit to include forms of benefit not directly related to the trial under 
consideration. 
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Specific Issues: 
- The concept of benefit in the literature on medical and health related research ethics 
- The modification of the concept of benefit in revised declarations 
- The concept of exploitation in the literature on medical and health related research ethics 
Analysis: 
1. Analysis of current theoretical conceptions of benefit and exploitation employed in the 
literature on international clinical research ethics.  
2. Analysis of empirical studies addressing the issue of globalization of clinical research 
and the issue of exploitation
1
.    
Summary of Chapters: 
Chapter 1: Ethical theories on Exploitation 
This chapter provides an analysis of ethical theories on exploitation with particular emphasis 
on the following issues:  
a) Different conceptions of exploitation in the literature on medical and health related research 
ethics.  
b) Current forms of consensus regarding the concept of exploitation - what do different 
scholars agree and disagree on.  
c) Forms of exploitation prevalent in medical and health related research, and  
                                               
1
 Petryna, A. 2007. Clinical trials offshored: On private sector science and public health. BioSocieties 2: 21-40. 
Glickman SW, McHutchison J, etal. Ethical and Scientific Implications of the Globalization of Clinical 
Research. New Eng J Med 2009, 360, 8:816-823. 
Chirac P, Torreele E. Globa Framework on Essential Health R&D. Lancet 2006, 367 (9522): 1560-61
.
 
Matsoso P., M. Auton, S. Banoo, H. Fomundam, H. Leng, S. Noazin. 2005. How does the regulatory framework 
affect incentives for research and development. Study Commissioned for the Commission on Intellectual 
Property Rights, Innovation and Public Health (CIPIH): World Health Organization. Accessible at: 
http://www.who.int/intellectualproperty/studies/Study5.pdf  
Solbakk JH, Vidal SM, Research Ethics, Clinical. In: Chadwick R (Ed.). Forthcoming in Encyclopaedia of 
Applied Ethics 2012 
Ballantyne A (2010) How to Do Research Fairly in an Unjust World. American Journal of 
Bioethics; 10(6):26-35Volnei Garrafa, Jan Helge Solbakk, Susana Vidal , Claudio Lorenzo   Between the needy 
and the greedy: The quest for a just and fair ethics of clinical research. Journal of Medical Ethics 2010; 36:500-
504, doi:10.1136/jme.2009.032656. 
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d) Based on the analysis of different conceptions and forms of exploitation, to assess the 
possibility of suggesting more sustainable concepts. 
Chapter 2: Development of the Concept of Benefit in Research Ethics 
A critical analysis of the concept of benefit and its development with special emphasis on:  
a) What is benefit?  
b)  How did the concept develop? Milestones/timeline of development of the concept in the 
scholarly literature in medical and health related ethics.  
c) The current conception of benefit in transnational research ethics and,  
d) Shift of benefit in terms of autonomy and decision making in medical research involving 
human beings eg. Bodies for sale? Docile bodies? etc. 
Chapter 3: Empirical Indications of Exploitation: Some Case Stories 
The core purpose of this chapter is to substantiate and demonstrate empirical indications of 
exploitation in medical and health related research activities in poor and low-income 
countries:  
a) Investigating the situation in Tanzania  
b) Tracing literature that inform about exploitation in Tanzania  
c) Discussion with members of functioning research ethics committees to find out: 
 their personal understanding of the concept of exploitation in a Tanzanian context, 
 if they can provide examples of studies that indicate different forms of exploitation, 
link of reported forms of exploitation in other documented case stories. 
Chapter 4: Analysis of the concept of Benefit in Current Declarations 
a) Declaration of Helsinki - How the concept of benefit has been modified during the 
different phases of revision. 
b) How the concept of benefit is expressed in other relevant declarations and guidelines 
(such as in CIOMS International Ethical Guidelines for Biomedical Research (2002) and 
the Universal Declaration on Bioethics and Human Rights (2005)). 
c) The position of benefit for research in poor and low-income countries 
d) Health needs and the “10/90” gap, a conception which refers to the mismatch in global 
spending on health research between affluent and poor and low-income countries. 
12 
 
e) How does benefit merge fairly? Or unfairly? 
f) How ethics scholars have tackled the concept of benefit and benefit sharing in research 
g) The use of placebo and the future role of the Declaration of Helsinki 
Rationale:  
This study has both theoretical and practical relevance. At the theoretical level, the study will 
contribute to the understanding of the concept of exploitation in medical and health related 
research ethics. At the practical level, the study will provide knowledge about current trends 
in transnational medical and health related research and a better understanding of current 
perceptions of benefit among researchers involved in such research. Furthermore, the hope is 
that it will contribute to a better understanding of the concept of exploitation, in particular 
during research undertaking.  
Dissemination of results 
Publications in international journals. Summarised version of some concepts and relevant 
chapters in a simple and understandable way to both researchers and research participants in 
poor and low income countries; presentations at local and international conferences just to 
mention a few means in which this work will be shared.  
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CHAPTER ONE 
ETHICAL THEORIES ON EXPLOITATION 
Introduction 
This chapter seeks to provide a thorough analysis of ethical theories about exploitation with 
particular emphasis on and discussion of different conceptions of exploitation especially in 
the literature on medical and health related research ethics. It also aims at discussing forms 
and statements regarding the concept of exploitation by examining debates in medical and 
health related research endeavours. Finally, the chapter will try to assess the possibility of 
suggesting a more suitable conceptual framework addressing the issue of exploitation, based 
on a critical analysis of current conceptions and forms of exploitation. 
Understanding exploitation as a concept 
Exploitation is not a new term; neither does it denote unfamiliar situations despite raising a lot 
of controversies and concerns within our time. A number of ancient literary sources have 
simply described exploitation as a way in which one group oppresses the other by not giving 
what it is supposed to receive after the agreed duty. Religious literature describes such a 
tendency as an open welcome of anger from a supernatural power. 
According to the Bible and the Quran for instance, God created human beings in his own 
image who should not be subjected to any form of exploitation, and punishment for 
exploitation is clearly expressed: 
“…I shall not turn it back on account of their selling someone righteous for mere silver, and 
someone poor for the price of a pair of sandals” (Amos 2:6 b)2.  
“Woe onto defrauders, those who when they take the measure from mankind, demand it in 
full but if they measure unto them, or weigh for them, they cause them less…” (Quran 83:1-
6)
3
. 
Both Christian and Muslim theology insist on honesty in dealing with other humans avoiding 
exploitation by paying them what they ought to receive in accordance with what they have 
                                               
2 New World Translation of the Holy Scriptures (1984)Watch Tower Bible and Tract Society of Pennsylvania 
New York 
3 As provided by Engineer A. from Islamic Economics: A progressive Perspective Occasional Papers No 8 Vol 7 
August 1991; Institute of Islamic Studies Bombay http://www.indiarightsonline.com/Sabrang/relipolcom81-
90.nsf/5e7647d942f529c9e5256c3100376e2e/f688802cf9475993e5256d760035252c/$FILE/ced01277.pdf 
accessed 01 October 2010 
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done, and not less. I could have gone further to explain other religious notions on exploitation 
such as e.g. in Buddhism where indiscriminate exploitation of both animals and human beings 
are one among the worst form of sins against God and no one can achieve re-birth after death 
without being weird against exploitation
4
 This, however, I consider beyond the scope of this 
discussion.   
From times immemorial, exploitation has been looked at with a slant eye. The advent of 
colonialism and subsequent establishment of empires in various parts of the world for 
example, have been linked with exploitation whereby the often spoken “master-slave 
relationship” has prevailed for centuries; to denote a predisposition of unfair treatments 
among one group of individuals in producing goods and services. Lots of spectacular and 
magnificent buildings and towers, huge ships, railways, heavy industries and the like, though 
aesthetically beautiful and/or useful, have been a result of many activities that require 
exploitation of both human and natural resources (Morris 1998). 
In a general sense, to exploit something means to take advantage of it and not to destroy or 
waste it (Wilkinson 2003). One can see this as a positive explanation for things like natural 
resources being obtained and used for beneficial purposes to human beings. On the other 
hand, the same term can be used in an evaluative or normative manner to indicate negative 
connotations when assessing the extent or burden of activities that are done by human beings 
when facilitating lucrative gains for a certain segment of a population or society. Exploitation 
in a moral sense means actions that make others suffer in a number of ways where in most 
cases the gains are hidden from the one who has been involved in producing them. In this 
manner, it can be argued, the one exploited is sometimes made unaware of exploitative 
intentions, plans or actions against him or her.  
Exploitation is an ambiguous and complex concept which it has proved difficult to come to 
terms with. Because of this ambiguity and complexity, it has raised many debates in various 
disciplines. Some examples of exploitation are focusing on personal intention of obtaining 
desired results such as “A weight lifter exploits his muscles to lift weights” or, “A carpenter 
exploits his tools to build beautiful chairs” (Hawkins and Emanuel 2008). These two 
examples, it can be argued, might fit in the materialistic point of view where commodities and 
valuable items are believed to determine all means to achieve the ends. Here for instance, a 
weight lifter is using his or her own muscles (and not the physical power of someone else) 
                                               
4 In Buddhism Core Belief at: http://www.religioustolerance.org/buddhism1.htm Accessed 30 September 2010 
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willingly and knowingly to achieve the ends of greater advantages and perhaps wealthier 
gains to him / herself. The carpenter does not chop off his own hand to make a beautiful chair. 
But if school children are employed in the factory and offered biscuits as a token, many would 
deem it unacceptable despite of the production of beautiful chairs. 
Kantian vs utilitarian theories on exploitation 
Two types of ethical reasoning originating from a philosophical understanding of the concept 
of exploitation are embedded within the theoretical frameworks of utilitarianism and 
deontological arguments. Systematic reflection on these theories is needed so as to have a 
comprehensive clarification in dealing with practical ethical problems we encounter (Tanner, 
Medin et al. 2008). According to utilitarian theories, the moral character of an action can be 
assessed with a view to the consequences (in terms of harms or benefits) it brings. In this 
premise, good intentions are always assisted by the right actions to produce the best outcomes 
(consequences), and bad consequences are a result of bad intentions preceded by bad actions 
(Alexander and Moore 2007). Therefore in this analysis, conclusions about what is wrong or 
right are based on the consequences as illustrated in the following diagram: 
 
 
 
 
Fig 1: Interlink between intentions, actions and consequences (as conceptualized by the 
author).  
As arrows in the above diagram indicate, assessment of exploitation can be done by looking at 
a combination of intentions and the subsequent actions which are inter-linked to cause 
consequences.  
The concept of exploitation may be expressed within this framework with the meaning that 
we must have intentions in order to act in a way that will result in exploitative consequences. 
Among the easy and prevalent views especially in medical and health related research, have 
been those looking at exploitation by judging the consequences in terms of actions or vice 
versa; without looking at intentions. For instance, let’s say a research participant has 
encountered adverse effects of a drug on trial. Critical assessment of exploitation in this case 
Intention 
Action 
Consequence 
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would be the answer to the question: Did researchers intend to inflict harm to participants? Or 
rather, what was the intention behind this study? I believe that any obtained answer if 
correctly placed within this framework can lead us to give the true judgement of exploitation. 
Most utilitarian view supporters propose producing the greatest amount of good for the 
majority of the population. Therefore, the so called “negative utilitarianism” stance is applied 
in order to minimize the amount of harm for the greatest amount of the population. It is 
further argued that this is the most effective ethical practice because there are more ways in 
which harm is inflicted to individuals than good; and the greatest harms are considered more 
consequential than goods. There are many different forms of utilitarianism, but the two most 
well-known are act-utilitarianism and rule-utilitarianism. Act utilitarianism on one hand, 
focus the attention on each individual act, and chooses that individual act which will generate 
most happiness. Rule utilitarianism, on the other hand, focuses the attention on potential rules 
of action. Therefore, in order to determine whether the rule should be followed, or not, it is 
important to identify which rule would give rise to most happiness if it was adhered to by 
everybody. This suggests an obligation of strictly acting according to the given rules that aims 
at bringing about the most happiness. 
The moral status of medical and health related research relies upon the ends rather than the 
means under utilitarian theories. For instance, according to utilitarianism a study that would 
promote social goods for many can be justified, even if those who are involved in research are 
generally weak and those who enjoy the end product of research would be typically well off.  
In deontological ethics (also known as duty based or right– based ethics ), the understanding 
of what is right or wrong is built upon considering the values, rights and duties (or principles). 
Thus, deontological ethics holds that some actions would be condemned due to their nature 
and that if an action is not corresponding to anticipated rights, then it is morally not permitted. 
Most advocates of deontological ethics argue that an action might be considered wrong 
regardless of its likelihood of bringing good to the majority. Such a consideration is taken if 
the action seems to violate the right or duty based ethics and established rules that can serve 
as the basis for making moral decisions for specific situations (Teson 1992; Payne 2006; 
Pellegrino 2009; Williams 2009). 
Those who look at the concept of exploitation from the vantage point of a deontological 
theoretical framework argue that it must be considered morally wrong to involve vulnerable 
populations in medical and health related research due to the nature and complexity of their 
17 
 
life situations. For example, the often criticized are situations where children or sick 
individuals are involved without their awareness. For deontologists, the conformity to moral 
norms is the most important no matter good the act would bring.  
Forms of exploitation in medical and health related research  
There is no doubt that medical and health related research involving human beings has 
improved the treatment, care, and well-being of people in the world. This is because the end 
point of this kind of research activities is the knowledge that will be generated and which is 
expected to not only be beneficial among individuals involved in the research but also to the 
group of patients suffering from the same ailment as well as to the society as a whole. Despite 
development of medical and health related research and its positive outcomes, some concerns 
have been raised about two groups of researchers: First, those who are interested in doing 
research to advance knowledge while at the same time being observing the likely harms that 
might occur to research participants; and second, those who while they are engaged in 
developing knowledge, they purposely involve vulnerable research participants in studies 
without due consideration of the associated potential risks to them (Benatar 2004). Some 
moral and ethical principles have been proposed and eventually applied when conducting 
studies that involve human participants. Most of these principles insist on respect for human 
dignity and adherence to the social benefits that would lead to acceptable standard of life as a 
result of participating in the said study. Therefore, sometimes calling a study exploitative 
would require more consideration of the benefits accrued from it in relation to its ethical or 
unethical conduct (Resnik 2003). There are special cases, however, where some medical and 
health related research activities have been documented as scandalous to a large extent. The 
following table provides a detailed summary of some of these studies: 
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Accounts of selected documented unethical studies among vulnerable groups: 
Study Years Details 
Pfizer sponsored Meningitis 
epidemic study – Nigeria 
1996 Study sought to curb a meningitis 
epidemic in Kano, Nigeria, using a trial 
antibiotic namely trovan which was yet 
approved to be used by children. 
“Eleven children who received that 
experimental drug died and 200 others 
became deaf, blind or lame”(Macklin 
2004; Lysaught 2009). 
The Tuskegee syphilis study 
among poor Black-
Americans in Alabama, 
USA 
1932-1972 The U.S. Public Health Service aimed 
at documenting the natural progression 
of syphilis among black-Americans 
despite the discovery of its cure. 
Participants were denied treatments and 
were not even told about their disease 
(Brandt 1978; Gamble 1997). 
A series of human 
experiments among patients 
of Vipeholm Mental 
Hospital in Lund, Sweden 
1945-1955 To determine the effects of 
carbohydrates in the formation of 
cavities. Participants were intentionally 
provided with excessive sugar to 
encourage tooth decay. Up to 1949 the 
teeth of about fifty of 660 participants 
were completely destroyed (Krasse 
2001; Wikipedia 2010). 
 
Willowbrook School Study 
New York State, USA 
1963-1966 A study aimed at finding out the 
effectiveness of hepatitis vaccination by 
intentionally infecting mentally 
handicapped children with hepatitis 
virus either orally or by injection 
(Rothman 1982; Ethics 2010). 
Jewish Chronic Disease 
Hospital Study in New York 
City, USA 
1964 A study aimed to develop information 
on the nature of human transplantation 
rejection processes. Patients without 
cancer were injected with live cancer 
cells. Investigators didn’t tell the 
patients to avoid scaring them, and also 
with a belief that the cells might be 
rejected (Standler 1997; Lerner 2004). 
 
Table 1: Summary accounts of abusive studies in medical and health related research 
In these, and more studies, not only were the rights of study participants violated, but also in 
some circumstances their health were compromised leading to research associated deaths 
(Emanuel EJ 2004). Although atrocities in research have been documented globally, 
historically those that happened in poor and low-income countries have rarely received the 
same attention (Macklin 2004). The most recent disclosure of unethical research relates to a 
60 years old study involving U.S. medical researchers who in the period of 1946-1948 
intentionally gave a group of Guatemalans gonorrhea and syphilis to study the diseases 'in 
vivo' (http://www.msnbc.msn.com/id/39463624/ns/health-health_care/):(Frieden and Collins 
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2010; Solbakk 2010). This, not only adds to many unethical studies that have been 
documented previously, but also rings an alarm bell perhaps necessitating a new look in order 
to strengthen the guidelines and regulations, which have been put in place to guide medical 
and health related research involving human beings all over the world.  
 
Among important questions one can ask are if it is morally permissible for scientists to 
intentionally inflict harm in the name of science with confidence that one day the president or 
principle investigator will come out with a statement of apology. The other could be if 
compensation will be made enough to cover for the lost lives as a result of such kind of 
vicious experimentation. Critics of trends in medical and health related research activities 
conducted in impoverished communities argue that; they are “potentially exploitative because 
of poverty”. Also “Lack of human and material resources, illiteracy and poor leadership styles 
in most of these countries make it an easy, cheap and convenient place to conduct human 
research” (Lavery 2007).  
Competing conceptions of ‘exploitation’ in medical and health related research ethics 
Two types or forms of exploitation have been debated for a long time. The first is called 
“Harmful and Non-consensual Exploitation” where potential harm is inflicted to individuals. 
As Standler puts it, “…non-consensual experiments are often performed on captive people in 
an institution, particularly people who society has regarded as less worthy” (Standler 1997). 
The harmful non-consensual exploitation can be seen in trials (like the famous 1940’s Nazi 
and Tuskeege experiments) which were performed on participants without their consent while 
researchers either gave incorrect or no information. In general, such or similar 
experimentations are said to have no importance or benefit to the involved population. 
The second form is called “Mutually Advantageous and Consensual Exploitation” (MACE) 
which involves agreement between the two parties with sharing of advantages between them 
(Wertheimer 2008). In this manner of sharing it doesn’t matter whether one part gets more 
advantages than the other as long as there is an agreement between them. To illustrate this, 
Wilkinson gives an example of characters A and B where B is unemployed, has no food and 
is in danger of losing life if he doesn’t get food soon. There are no other alternatives like 
charities or social welfare services around, and he cannot commit a crime because he lives 
near the police premises. A has a factory and offers B a job but he has to do 50% more work 
and also accept 70% less pay. B accepts the terms in order to survive (Wilkinson 2003). In 
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this example there is a mutually advantageous exploitation since A has taken advantages of 
B’s situation. At the same time there is a consensual exploitation since B has willingly 
accepted to work under exploitative terms in order to survive. Similar to this example might 
be that of a poor person who accepts to sell one of his or her kidneys in order to better provide 
for the family. In this kind of exploitation, exploiters are said to take advantages of the 
exploited, but we are urged to believe that the exploited agreed and consented for the 
transaction because of a kind of benefit they feel they will get from it. 
There exists a lot of differing and competing conceptions of exploitation put forward by a 
number of scholars in medical and health related research ethics though. Among them is the 
one criticizing the method used for clinical trials where available interventions are not 
provided to research participants during the process. In such trials, there is a tendency of 
comparing efficacy of active treatments to one group of participants and without treatment 
(placebo) to the other. In this view, medical and health related research is considered 
exploitative and unethical if researchers would withhold available treatment intentionally in 
order to measure effectiveness of a new intervention on test (Bayer 1998; Emanuel and Miller 
2001). 
Other exploitation claims include unavailability of the products resulted from interventions 
tested in poor and low income countries. It is argued that, any medical or health related 
research is deemed exploitative if the gained knowledge seems not to benefit the host country 
in which it was conducted. This is more evident when the developed drug is not available due 
to high prices or if that drug was not meant to help solving the existing burden of disease in 
the host country (Garrafa, Solbakk et al. 2010). 
There are also questions about the level of knowledge and economic situations possessed by 
research participants. It is claimed that some researchers tend to take advantage of 
circumstances caused by poor health care access and little knowledge about research among 
participants in poor and low income countries (Macklin 2004; Voo, Chin et al.). In such a 
situation, exploitation seems to be obvious among research participants who miss the 
expected outcomes.  
Another similar exploitative situation has been termed ‘globalization of clinical research’, 
which is said to be manifested in the increased number of clinical trials carried out or 
sponsored by the drug companies in poor and low-income countries. Such trials are 
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formulated within the framework that they can be accomplished quickly with less supervision 
and thereby produce drugs in question as soon as possible (Glickman, McHutchison et al. 
2009). It is believed that research participants are manipulated due to existing disparities in 
terms of education, health care systems, income and the general social welfare. 
Some other scholars have come up with what is known as the ‘permitted exploitation 
principle’ which states in part that “it is wrong to interfere with or seek to prevent transactions 
that are beneficial to the parties involved even if the transaction itself is unfair, unjust, or 
exploitative” (Mayer 2007). This principle seems to put a barrier with regard to interfering in 
exploitative practices which undermine the other part. It can be argued that if medical and 
health related research work is exploitative it should not be permitted regardless of 
transactions. One can argue that there are no acceptable reasons for putting individuals into 
risks simply because they have accepted to join the study due to any condition (such as social, 
economic, political or cultural vulnerability).  
Forms of exploitation in medical and health related research ethics: Current debates and 
consensus 
a. The paradox of informed consent 
The right of research participants to decide for themselves in a free and informed manner is 
considered a key principle in all guidelines regulating research that involve human beings. 
The original informed consent procedures originate from the post-world war II Nuremberg 
Medical Trial, which having gone through legal and ethical considerations, realized that 
almost all medical experiments conducted during that time were unethical and did not 
consider human participants as autonomous individuals. Most of these experiments led to 
death or permanent impairment to people who were forced to participate. The Doctor’s trial 
resulted in the so called “Nuremberg code”, in which voluntary consent is deemed absolutely 
essential. In addition, the code emphasises the importance of protecting human research 
participants by providing clear information on aspects such as potential harms that could 
happen during research, considerations of individual understanding and autonomous decision 
making. (Weindling 2001).  
Despite the Nuremberg code, and other subsequent guidelines and declarations pertaining to 
medical and health-related research involving humans, there have been a lot of 
misunderstandings over how valid could informed consent be, especially in cross–cultural 
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settings where individual consent is considered not enough. It is argued that, in all these 
settings informed consent is always being compromised by less autonomy making it 
sometimes difficult to obtain as required (Benatar 2002). If this is the case, it can be argued, 
that informed consent cannot be taken for granted, since the conditions under which research 
participants are recruited can vary a lot from place to place.  
The so called “voluntary informed consent” has been exhaustively discussed over the years 
ranging from verbal, written (and signed either with an inked thumb or pen), communities / 
group consent up to the current electronic (e-consent) that can be achieved via established 
modals in specific settings such as hospitals and the like (O'Keefe, Greenfield et al. 2005). 
Greater concerns have been put on the type and amount of information that participants ought 
to receive and how long the informed consent document is supposed to be in order to provide 
clear and precise information. The other is the capacity for research participants to understand 
scientific terms such as “randomization”, “double blind”, “placebo”; and much more 
(Appelbaum, Roth et al. 1987). These are just a few among many channels in which 
exploitation might occur. It can be argued that no matter how one agrees with regard to 
participation in a study, there remains a controversy on how the study in question maintains 
the integrity of the participant in all stages.  
b. The question of payment or compensation for research participants 
The other often criticized trend is the question of compensation to research participants in 
which exploitation occurs due to interactions between researchers and participants. An 
interaction is deemed intimidating in the presence of less or no compensation, when 
participants volunteer to participate in research either due to their weaker economic position 
or due to attractive compensation that tend to ‘blind’ the forthcoming risks as a result of their 
participation (Lemmens and Elliott 1999). In their provocative article “Guinea pigs on the 
payroll: The ethics of paying research subjects”Lemmens and Elliot insist that healthy 
participants become vulnerable because of their financial needs while if patients agree to 
enroll in the study it might be because of their medical condition which they believe will best 
be taken care of. In this situation research is considered exploitative though apparently it 
might have been agreed upon and precisely documented. 
c. Risk vs. Benefit ratio  
In her tentative definition of exploitation Macklin (2004) says (though without applying it to 
specific research involving humans), “it occurs when wealthy or powerful individuals or 
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agencies take advantage of the poverty, powerlessness, or dependency of others by using the 
latter to serve their own ends …”  This argument is also supported by the so called “unfair 
and uneven distribution of risks”(Emanuel, Wendler et al. 2004; De Castro 2007) whereby 
one group of population seems to bear all responsibilities and consequences of medical and 
health related research activities despite social, economic and political constraints and the 
other group receive the end results. 
Towards a more sustainable conception of exploitation 
It is often difficult to answer if conceptions can be sustainable because of changing ideas from 
time to time. It is sometimes difficult also to refute different conceptions as given by 
respected scholars without considering their social, political, economic, cultural and even 
linguistic inclination. Perhaps it is important to understand that most of these conceptions 
have been developed within the framework of an array of different understandings of the 
world which might not be universal. In the beginning of the years 2000 Benatar wrote an 
article “Reflections and recommendations on research ethics in developing countries”. In this 
article he gave a complex narrative of a pregnant mother from one of the poorest countries of 
the world who is asked by collaborative researchers to participate in HIV research despite 
inadequate health care facilities and her little understanding of the disease and research. 
Several unanswered questions are raised as the participant doesn’t understand why she should 
be studied and if her spouse or community members will agree, and more importantly what 
will happen to her and her baby after the study is completed. She is not alone, for most of 
such questions are often not answered due to already established frameworks in which 
according to Benatar, “the privileged lives have been constructed and maintained through 
modern and sophisticated methods of exploitation of people across the globe” (Benatar 2002).  
 
The fact that prominent researchers, sponsors or drug manufacturing companies may have 
much more gains than research participants in poor and low income countries, can be 
correctly considered as a platform for attention to design studies that should protect these 
participants. Unfortunately, this platform is being dimmed by power relations and it is always 
weak due to contorted theories and academic arguments to the extent that study participants in 
these countries are taken for granted. The promotion of human health should go hand in hand 
with proper protection of anticipated risks and clear focus on the kind of benefits to both 
study participants and the intended population. I would like to suggest some few 
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considerations when looking at the concept of exploitation with an eye of a person from a 
poor and low income country: 
i) When the researcher employs “hidden risks” as a strategy to obtain consent for the 
participant to enter the study that he or she would have rejected if correctly informed. 
ii) When vulnerability in terms of both economic and social welfare are used as a means to 
allure the research participants to join a study whose products would be unaffordable or else 
having no meaning to them at the end. 
iii) When more risks than benefits are anticipated.  
Key issues in this argument are risks, vulnerability and benefits and I suggest that a 
sustainable concept of exploitation in medical and health related research ethics should reflect 
these issues: Medical or health related research activities undertaken among a vulnerable 
population due to their social, cultural, political, and economic or any situation without their 
understanding of the risks or beneficial outcomes. 
Summary and concluding remarks 
This chapter does not have a great deal to say about religious conceptions of exploitation, 
rather some stand points have been used to explain how the concept has evolved among 
human beings since ancient times. On one side, the concept has been used to denote 
economical oppression in materialistic contexts whereby individuals are said to be exploited 
when working for the others and receive undue payments. On the other side, according to 
medical and health related research ethics, the concept developed on the historical background 
of atrocities and unethical controversies where individuals have been subjected into harm and 
even death during research without their knowledge. The proposed three key issues: Risks, 
vulnerability and benefits should be adhered to when trying to discuss issues pertaining to 
exploitation in the context of medical and health related research ethics. 
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CHAPTER TWO 
DEVELOPMENT OF THE CONCEPT OF BENEFIT IN RESEARCH ETHICS 
Introduction 
A critical analysis of the concept of benefit and its development in medical and health related 
research ethics is undertaken in this chapter. Major focus is on the discussion of this concept 
in the literature. The current discussion on benefit sharing in medical and health related 
research between affluent and poor and low income countries is also discussed; and a shift of 
benefit in terms of autonomy and decision making process in medical and health related 
research involving human beings (e.g. bodies for sale, docile bodies?) is also addressed. 
What is benefit in medical and health related research  
The importance of medical and health related research lies on a premise that if we know why 
people get sick, then we can be able to understand how to alleviate their suffering and 
improve their health. For several reasons it might not be easy to note the direct benefit in this 
type of research. For example, if a researcher is studying a problem that does not exist among 
the research participants involved; and the benefit generated from this research leads to 
helping patients located in a community in another part of the world, it is not clear whether 
and eventually to what extent such forms of benefit can be said to comply with the 
requirements in medical and health related research ethics. Most of the expected benefits 
however, might include issues such as better curative or preventive measures of a certain 
disease, improvement of health services, or proven existence of a certain health problem so 
that actors can start looking for solutions etc. Sometimes health research undertakings might 
be risky to participants and as a general requirement researchers are supposed to explain all 
possible risks before undertaking a study. In some areas of research these requirements are not 
adequately observed, and there are allegations that researchers have tended either to cause  so 
called “undue inducement” by providing a large offer of money or give “false hopes” or 
rather, “therapeutic misconception” to participants who take part in research studies 
(Appelbaum, Roth et al. 1987; Dickert and Grady 1999; Wertheimer and Miller 2008). 
The issue of benefit and benefit sharing in medical and health related research ethics has been 
the subject of intense debate during the past decades.(Glantz, Annas et al. 1998; Glickman, 
McHutchison et al. 2009; Garrafa, Solbakk et al. 2010; Lorenzo, Garrafa et al. 2010). The 
trend of using participants from impoverished communities for studies without a due regard 
of their economic, political and social vulnerability, the often called globalization or 
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“transnational” clinical research and the shift of trial sites to these communities plus 
investments in drugs trials that do not target the burden of diseases in poor and low income 
countries are just to mention a few debatable topics.  
Perhaps the most contradictory concerns are the ones involving how to determine 
involvements and distribution of benefits brought by individual research participants; and the 
question what kind of rights research participants have in relation to benefitting from research 
and which obligations researchers or sponsors have in this respect (Simm 2007; Johansen, 
Aagaard-Hansen et al. 2008). The literature is filled with accounts of cases where researchers 
have carried out studies among individuals or groups and reaped huge benefits while ignoring 
their participants. For instance, on the front flap of the book “The Immortal Life of Henrietta 
Lacks” Rebecca Skloot gives an account of a famous case from the1950’s: “Doctors took 
(Henrietta’s) cells without asking...” Such cells taken from Henrietta’s body did not die like 
others during experiments. These famous cells namely “HeLa” according to the two initials of 
her name, have led to the scientific discovery of a polio vaccine, and has been used 
extensively to researching effects of contaminations from toxic substances and much more 
(Skloot 2010). Since it has later been revealed that, Henrietta’s family has lived without even 
health insurance all these years, and their mother’s cell line has been used almost all over the 
world for medical experiments and discoveries without their knowledge, there is a 
questionable bill to settle as far as benefit and benefit sharing is concerned. 
Another astonishing account is that of St Martin Alexis whose gastric juice from the wound 
that caused permanent fistula on his stomach after a gunshot accident was used for studying 
the physiology of digestion (Markel 2009). It is documented that, despite the poor life 
condition, Alexis partially healed wound was left open and continued to be a source of 
obtaining gastric juice for experiments throughout the rest of his life. Such experiments 
brought out the praised outcomes of demonstrating the duration and the process of normal 
digestion and the influence of emotions and environment on the digestive actions; while at the 
same time treating Alexis as a “laboratory” or a “guinea pig”(Tanner 2000). 
 
Possibly another interesting account is that of blood samples which were taken from some 
members of a small hunters community in the Papua New Guinea; with a teasing information 
that researchers wanted to see an insect from their blood - whose discovery came out with 
existence of antibodies which were used to produce immortal cell line as the basis for 
leukaemia therapy (Emerson, Singer et al. 2011). Similar to Henrietta and Alexis, these 
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community participants were not aware of the discovery and subsequent experiments carried 
out on their body fluids. No doubt they remained poor while contributing to scientific 
discoveries that made scientists both famous and rich as a result of their research findings.  
 
Important moral questions that need to be asked are: What kind of right one has to claim 
unique characteristics of one’s own body tissue or cells? Can such tissue and cells be sold or 
compensated? If so, is uniqueness in humans taken and valued because we are humans? 
(Davis 2001). In contrast, what right does one have to use any body parts of another person 
for whatever reason without informing what is going on? These are just a few among 
questions that have been raised when discussing the meaning of benefit in health research 
involving human beings. 
 
Some researchers often refer human participants as ‘subjects’ or “cases” in many instances 
during medical and health related research and other scientific endeavours for that matter. 
Ironically, a subject in this sense is considered an object of inquiry. In my opinion, a subject 
doesn’t have any benefit on its own. One can get benefits such as knowledge, promotion and 
the like from mastering the subject. If that is the case, then a human participant in medical and 
health related research would be considered more or less the same as any object of study such 
as Biology, Physics or Engineering; in which an individual concentrates to gain knowledge 
and discover new things so as to become famous and receive a raise from the current position 
etc.  
 
Some scholars are arguing that determination of benefits to study participants should be 
considered on at least three levels: First being the target group - also called the “Who” - which 
includes study participants from the community or the host country where the study is 
conducted. The second level is the consideration of time or duration in which the study will 
take place, i.e. the “When”. This also ranges from the actual period of the study and the 
estimated time of services that will be rendered after the study is over. And the third is the 
kind of benefit to be provided, i.e. the “What”. Benefits to be considered in this endeavour 
would range from medical to non-medical related assistance during and after the study 
(Johansen, Aagaard-Hansen et al. 2008). Though simple as it seems to be, the suggested 
principle of benefit sharing is often not followed completely by researchers. Most studies tend 
to easily get the target group, consider the duration of the study and continue with the study 
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without considering what would be the benefit of that study to both the study participants and 
the community at large. The following section will discuss this tendency. 
Current trends of benefit sharing in medical and health related research 
The dramatic shift of location of clinical trial sites led by big pharmaceutical companies and 
at least two reputable USA National agencies, the National Institutes of Health (NIH) and the 
Centres for Disease Control (CDC) (Angell 2005); to poor and low income countries over a 
period of more than 15 years has raised a lot of concerns among scholars in research ethics. 
At least five possible reasons have been suggested by Glickman et al. to be the major driving 
forces behind this trend: One is cost saving. It is anticipated that substantial saving may be 
achieved by moving phase 2 and phase 3 clinical trials to places where lower salaries are 
normally paid to study coordinators and the supporting staff. The second is time saving. Since 
time costs account for 50% of costs to develop new drugs, therefore it is imperative that 
globalization of clinical trials may shorten the timeline for clinical testing and thereby reduce 
the costs. The third is easier access to potential research participants that will help speed up 
the recruitment process which is often long in other places. The fourth reason is an 
opportunity for fewer regulatory barriers in poor and low-income countries which helps to 
facilitate the conduct of clinical trials for pharmaceutical and device companies. And the fifth 
is the rise in regulatory barriers and concomitant costs in wealthy countries which speed up 
the outsourcing of clinical trials in poor and low- income countries (Glickman, McHutchison 
et al. 2009). Although it is widely accepted that effective treatments have to be made available 
to trial participants, this is often ignored on the basis of political, social and economic 
structural issues within the host countries. The new manufactured drugs resulting from 
various trials have further been expensive, unaffordable and sometimes not meant for either 
curative or preventive measures in the countries where such trials were conducted (Lavery 
2007; Voo, Chin et al. 2008; Garrafa, Solbakk et al. 2010). From the perspective of poor and 
low income countries, a study has no benefit if the population or at least the welfare of trial 
participants is not promoted. 
 
To curb the situation, implementation of the so called “post-trial benefits” approach has been 
recommended to mean that beneficial outcomes of the study ought to be discussed by both 
researchers and participants in the host countries before the start of the study in question, and 
most acceptable studies would be those responsive to existing problems that need to be solved 
(Zong 2008; Schuklenk 2010). One of the critiques raised against this approach relates to 
29 
 
difficulties in calculating the value of research and making a fair decision on who will receive 
benefits depending on the operating health system of the host countries (Voo, Chin et al. 
2008). Against such a critique, one can argue that the praiseworthy scientific and ethical 
studies would be those striving for finding solutions to both existing medical and health 
related problems among research participants; together with how weak systems can be 
improved for the welfare of present and future generations. 
Another alternative approach suggested in the literature is called “cautionary approach” which 
addresses the question of acceptability for researchers in industrialized countries to use 
citizens from poor and low income countries as research participants. This approach 
recommends that a successful research activity that involve vulnerable populations must have 
a direct benefit to that population and that there should be a realistic plan that would ensure 
provision of the new intervention resulted from such research (Glantz, Annas et al. 1998). 
This approach however, has been criticized as “procedural”, since it involves agreements 
between participants, researchers and sponsors who might have conflicting opinions in terms 
of fair distribution of benefits (London 2010). The procedural approach gives an account of 
agreements between sponsors, researchers, and participants on how research outcomes will be 
shared after a successful study. Ideally, this approach suggests a mutual creation of a 
distribution system that allows a fair share and equitable partnership between researchers and 
the involved communities.  
Angela Ballantyne in the paper “How to do research in an unjust world” (2010) proposes the 
Maxmin principle which would determine fair distribution of basic goods in the context of 
international research. The said principle requires more advantage of benefits distribution to 
be focused on the vulnerable communities during transaction, because of the evident weak 
bargaining capacity and lack of basic goods and decent social life among them. Therefore, in 
order to implement this principle, a global research tax should be applied where research 
sponsors would be made to gain a minimal benefit in a way that the surplus is distributed 
more to the vulnerable research populations (Ballantyne 2010). Some of the criticism against 
the proposed global research tax is that if host countries would receive tax revenues for 
research, then this would attract poor and low income countries to participate in any research 
as much as they can even by force from their governments (MacDonald and Walton 2010). 
Doubtful feelings are that fraudulent researchers can easily use this approach in poor and low 
income countries to negotiate with the type of dishonest and insensitive leaders; who would 
accept their fellow citizens to be enrolled and hence involved into risky studies.  
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It has further been envisaged that sponsoring companies may not be ready to pay tax and if 
they do so, then they may even prepare false contracts so that the resultant products will be in 
favour of their legal and intellectual properties in order to determine the price they want 
(McMillan 2010). This imagination stems from the fact that, still at present, most research 
results and products are mostly not available or affordable in poor and low income countries 
where studies are done.  
Further concerns that have been raised against the global tax for research are that big 
pharmaceutical companies would complain to the World Trade Organization using other 
companies like those of oil and household appliances, as a point of reference since they might 
not face the same stern global tax strategies, something which could jeopardize the current 
relationship between affluent and poor and low income countries (Resnik 2010). One can 
argue that the present or future relationship between nations should be strengthened and built 
upon a process which strives to find out how medical and health related research can be used 
to improve people’s lives while minimizing risks among participating vulnerable individuals 
at any point of their existence. 
According to the viewpoint of the “fair benefit approach” (Emanuel 2002; White 2007; 
Wertheimer 2008;) it has been suggested that research activities in poor and low income 
countries should be done within a framework that would fit into providing a guarantee of 
health care services that are not for the study in question among participants, plus improving 
the public health care services to reach even those who are not involved in the study. This 
may also include employment and other economic activities plus long term research 
collaboration A clear temptation for this kind of sacrifice comes from negotiated benefits 
which might not be responsive to the health needs per se. Suggested benefits such as 
employment or economic activities are just a few of such negotiations. Therefore, the 
approach cannot be really fair since it creates a dual manipulation in terms of interactional 
relationship between a) research group and community leaders and b) Community members 
and their leaders where the later means that community members would be incited to join in 
the studies following the former unfair negotiations between leaders and researchers and 
research sponsors. Although the perspective of fair benefit has been the mostly advocated, one 
can see it as a free way to mutually advantageous exploitation with the understanding that 
there might not be any difference between research participants and any individual who would 
agree mutually (hence fairly?) to accomplish any agreed activity despite its risk. 
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The alternative of applying the human rights based approach to international research using 
the so called Global Burden of Disease (GBD)-oriented research incentives has been a matter 
of discussion in recent years. In this approach agreement for rewarding the patent rights 
proportional to GBD together with mass production of the discovered drugs would not only 
make the new drug available but also affordable for the community members in order to curb 
the GBD (Pogge 2007). Among the challenges for implementing this approach is the Trade-
Related Aspects of Intellectual Property Rights (TRIPS) where mass production of the 
discovered essential drugs has financial implications and therefore the patents are “restricted” 
by intellectual property rights for both innovative and financial reasons by drug manufacturers 
to the extent of being difficult to be distributed “freely”. For that reason it is suggested that 
such essential medicines should not be considered as limited commodities inaccessible due to 
TRIPS but as free to be accessed by any drug manufacturer in the world to use for generic 
drug production which will enhance affordability and availability among impoverished 
communities. To retain income for the original drug producer and the associated innovation, 
alternative incentive for research must be established (Solbakk 2011). Ideally, it is anticipated 
that if patent holders and generic drug producers would agree with each other, their 
collaboration will result into making medicine available to the poor patients notably those 
with chronic diseases and also for preventive interventions. I think this is a promising 
approach though there are always resistances when it comes into money and rigorous cost, 
benefit and effectiveness analysis which might be a barrier. Moreover, most views on this and 
other approaches are only suggestions which require responses especially from the giant 
pharmaceutical companies which invest a lot of money in research and subsequent drug 
manufacturing and, of course, dictate on the prices and patent rights. 
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The question of autonomy, decision making and benefits in medical and health related 
research 
Among other troubling issues in medical and health related research are how the process of 
individual decision making to take part - or not part - in research can be realized, both among 
researchers and participants. Some scholars argue that one should be left to make personal 
decision while others argue that participants must be led step by step in understanding the 
likely risks and benefits in an anticipated study. It might be surprising if one can be ready to 
join risky research without determining the outcomes, although for some moral reasons there 
are those who are ready to offer their body parts for the sake of saving their relatives or best 
friends and thus accept even to shorten their lives in this process. 
Nevertheless, the most disturbing accounts are where human organs from living people are 
stolen in a number of ways for transplantation to others. It has been reported in many 
instances that people are killed and their body parts such as eyes, skin, kidneys livers and 
more are taken away to be traded (Becker 1999; Wilkinson 2003). Perhaps this tendency has 
something to do with legal actions because human body parts trade is not acceptable in many 
parts of the world and it doesn’t even sound correct seeing someone selling say a human heart 
in the established market if any. 
Another astounding account is the mistrust between researchers and citizens from poor and 
low income countries when human tissues and samples are sought for research purposes. This 
mistrust stems from a failure of researchers who collect samples from research participants 
without proper informed consent and leave without returning any meaningful benefit to the 
studied population (Emerson, Singer et al. 2011). As a solution, Emerson et al proposes the so 
called “tissue trust” arguing that “preventing exploitation and restoring trust while 
simultaneously promoting global health research calls for innovative approach…”. In my 
opinion such a trust can be built upon answering basic questions that seeks justification as to 
why samples should be shipped outside the host countries and how should they be archived or 
disposed of after the study is over. Ignoring this fact will be considered like that tendency of 
researchers from affluent nations looking for “docile bodies” as illustrated by contemporary 
bioethicists (Lysaught 2009). This tendency can furthermore be illustrated in contrast to the 
African view of human person where one cannot just use another as an object of contempt and 
ridicule since each, apart from being interconnected, has spiritual elements that can be 
understood in a complex divine world view (Gbadegesin 1993; Metz 2010). I know that 
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communities have attachments not only to each other but also to their body parts including 
tissues, fluids etc. I won’t be surprised if a researcher is asked to bring back blood samples 
after analysis, an agreement that is impractical in biomedicine! Therefore making a clear 
explanation that will not bring conflicts in terms of these endeavours is crucial. 
Summary and concluding remarks 
A critical analysis of the concept of benefit and its development in research ethics as provided 
in this chapter, is based on arguments which try to address the involvement and distribution of 
research outcomes between researchers, sponsors and people involved as participants in a 
given study. The current views on benefit sharing in medical and health related research 
between affluent and poor and low income countries are based on some proposed approaches 
from a number of scholars of medical and health research ethics. Three of these approaches 
are the global health research tax approach, the global burden of disease incentive and the fair 
benefit approach. As indicated in the chapter, there is a shift of benefit in terms of autonomy 
and decision making where sponsors of the “for profit making” type of research tend to ignore 
the welfare of vulnerable participants, thus using leaders from poor and low income countries 
to “allure” their citizens to enroll for studies that are non-responsive to medical or health 
related problems in their communities. Unfair benefits such as employment or financial gains 
have been discussed as unacceptable. The major conclusion of this chapter is a call for a new 
strategy that would make both parties responsible and accountable especially in providing 
clear explanation of the research process including proper informed consent in matter 
pertaining to samples, tissues and benefits in order to make medical and health related 
research acceptable and helpful to current and future generations. 
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CHAPTER THREE 
EMPIRICAL INDICATION OF EXPLOITATION: SOME CASE STORIES 
Introduction 
The core purpose of this chapter is to substantiate and demonstrate empirical indications of 
exploitation in medical and health related research ethics in poor and low-income countries. 
Particularly, it aims at investigating and analyzing the situation in Tanzania by tracing 
literature that addresses the issue of exploitation. The chapter further aims at integrating ideas 
and opinions from some members of functioning research ethics committees on their personal 
understanding of the concept of exploitation in a Tanzanian context, as linked with the 
investigated indications of exploitation in documented case stories.  
Tanzania: Location, background and political landmark.  
‘The United Republic of Tanzania’ 
shortly Tanzania, is located along 
the Eastern part of Africa, 
bordering the Indian Ocean 
between Kenya and Mozambique. 
The country got its independence in 
1961 from the British preceded by 
the Germans after the Second 
World War. English and Kiswahili 
are the official languages though 
there are over 130 local 
vernaculars. As indicated on fig 1, 
other neighboring countries are 
Uganda, Rwanda, Burundi, The 
Democratic Republic of Congo (DRC), Zambia and Malawi. Presently, Tanzania is a 
multiparty state led by the president of the union consisting of the mainland and the major 
island of Zanzibar with two isles, namely Pemba and Unguja, which remained to be the part 
of Arab sultanate of Oman since 1832 until independence (Jenkins, Mussa et al. 2011). The 
current Tanzania population counts 41,892,895
5
. The National Assembly with elected 
parliament members is the law-making body. Administratively, the country is subdivided into 
regions, districts, wards and villages where the central government and the local government 
                                               
5 As documented by CIA World Fact Book Available at: https://www.cia.gov/library/publications/the-world-
factbook/geos/tz.html Accessed February 7, 2011. 
Fig 1: Map of Tanzania Available at: 
http://www.mapsofworld.com/tanzania/tanzania-political-map.html.  
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are both legal and political entities. The legal system is governed by the Constitution of the 
United Republic of Tanzania (URT 1998). 
 
There exists a rich literature that explains the SOCIO-political, economical, historical and 
geographical features of Tanzania as among the center of attraction for exploration in terms of 
trade, tourism and research. It is from this background that I will draw a foundation for 
discussing how medical and health related research activities are regulated before discussing 
the conceptual understanding of exploitation in a Tanzanian context. This I will do by 
focusing on a set of research case stories and reports indicating exploitation.  
 
Brief account of the development of medical and health related research in Tanzania 
Organized scientific research dates back to the colonial era prior to Tanzania’s independence 
in 1961. The first establishment of a research institution in the country was a veterinary 
laboratory which was established in the central part of the country by the Germans in 1905; 
followed by the establishment of malaria, virology, and trypanosomiasis research centers by 
the British from 1919 (Mukama and Yongolo 2005). More such institutions were established 
after Tanzania won its independence, through the assistance of the United Nations, 
Educational Scientific and Cultural Organization (UNESCO). Several public health 
institutions serving as research centers were also built. Establishment of independent research 
institutions and universities also was a promising movement towards scientific research, as 
was collaboration with researchers and their institutions from abroad.  
Like many other poor and low income countries, Tanzania has always been faced with 
institutional constraints in conducting medical and health related research. Furthermore, 
several state regulations have been dwindled by a shifting historical context of political and 
economic conditions (Songstad, Rekdal et al. 2011). Coupled with poor infrastructure, 
communicable and non-communicable diseases just the same as other poor and low income 
countries, Tanzania has in recent decades witnessed the influx of researchers sponsored by 
different organizations from foreign universities and drug manufacturing companies, working 
in collaboration with local universities and research institutions in medical and health related 
research activities.  
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Legal guidelines for medical and health related research in Tanzania 
There are several legal guidelines made up by statutory bodies mandated by the United 
Republic of Tanzania, to approve and monitor research undertakings in all aspects. Here I will 
briefly present those dealing with medical and health related research.  
The National Institute of Medical Research (NIMR) 
The NIMR was established by the United Republic of Tanzania government Act no 23 of 
1979, with responsibilities to control, coordinate, register, monitor, evaluate and promote 
medical and health research designed to alleviate diseases. The institute has a duty to grant 
ethical clearance for all medical and health related research to be conducted in the country 
(URT 1979). Together with the local research ethics committees, the institute reviews all 
proposed medical and health related research projects before issuing ethical clearance. 
 
The Tanzania Commission for Science and Technology (COSTECH)  
COSTECH was established by the government Act no 7 of 1986 and is responsible for 
research promotion and coordination. It offers research clearance permits for all foreign 
researchers, Tanzanians studying abroad and in need of doing research in the country, and all 
Tanzanians except employees and students from institutions of higher learning as well as 
employees of affiliated research institutions who are required to do research as part of their 
duties (URT 1986). Despite this provision, some foreign sponsored research activities do not 
follow this regulation after obtaining ethical clearance from NIMR. The act does not contain 
any provision to deal with those who do not comply with the requirements of COSTECH. 
 
Tanzania Commission for AIDS (TACAIDS)  
The TACAIDS was established under the Act no 22 of 2001. It is an independent institution 
related to the Prime Minister’s office. Its major function is to formulate policy guidelines 
pertaining to the HIV/ AIDS epidemic and the management of its consequences in mainland 
Tanzania. In addition it is responsible for developing the strategic framework and planning of 
all HIV/AIDS control programmes and activities, including research (URT 2001). 
 
The Tanzania Food and Drugs Authority (TFDA) 
The Tanzania Food and Drugs Authority (TFDA) was established under the Tanzania Food, 
Drugs and Cosmetics Act No 1 of 2003. It has, among others functions, the function of 
regulating all matters relating to quality and safety control of food, drugs, herbal drugs, 
medical devices, poisons and cosmetics and to ensure that clinical trials on drugs, medical 
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devices and herbal drugs are being registered and conducted in compliance with accepted 
standards (URT 2003). 
 
Policies and ethical guidelines for medical and health related research in Tanzania 
There are lots of both national and international guidelines aimed at fostering the ethical 
conduct of medical and health related research. All documents of this nature have no legal 
binding; rather they function as walking sticks and they are subject to revisions from time-to 
time. At the moment there is no mechanism in place to deal with violation of ethical rules and 
regulations pertaining to medical and health related research, at least not at the national level.  
 
The National Policy on HIV/AIDS 
Established under the Prime Minister’s office in 2001, the policy has outlined the following 
ethical guidelines regarding HIV testing and research: 
For voluntary HIV testing, pre-and-post-test counselling shall be done to enable test results to 
be communicated to the person tested or, in the case of minors, to parents or guardians.  
For unlinked HIV testing, no pre and post-test counselling shall be required. For blood donors 
who wish to know their test results, provision shall be made for follow up voluntary HIV 
testing with pre- and post-test counselling. 
All HIV Testing shall be confidential. The public health legislation shall be made to authorize 
health care professionals to decide on the basis of each individual case and ethical 
considerations, to inform their patients or sexual partners of their HIV status. Such a decision 
shall only be made in accordance with the criteria such as proper counselling, informed 
consent, ethical clearance and professional conducts (URT 2001). 
 
The National Health Research Ethics Review Sub-Committee 
The National Health research Ethics Review Sub-Committee was established in 2001 as a 
sub-committee of the NIMR and issues Guidelines on Ethics for Health Research in Tanzania. 
The guidelines provides for the observance of the rights of research participants, need for 
researchers to strictly observe confidentiality and protection of research participants in both 
controlled and epidemiological studies (NIMR 2007). 
Implications of this arrangement in terms of research conduct and. exploitation in a 
Tanzanian context 
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Despite elaborative guidelines there have been a kind of mixed understanding as far as 
professionalism, political positions and statutory regulations pertaining to medical and health 
related research conduct in Tanzania. Some of these are manifested in the duplication of 
responsibilities which are said to have been a source of the so called “inertia” and henceforth 
dumps the vulnerable population into risky research. As will be discussed in the subsequent 
sections, there is an apparent tendency of dishonest researchers to take advantage of a loop 
hole in this system; thus conducting unethical and exploitative studies among the poor and 
vulnerable participants who do not understand the process of research. 
 
But perhaps we need to have a clearer understanding of the concept of exploitation in a 
Tanzanian context at this juncture. Two Kiswahili terms are used locally to denote almost the 
same meaning: One is called Unyanyasaji derived from the verb nyanyasa which means a 
tendency of someone to take advantage of another due to weaknesses. In this, the weaker one 
is aware of what is going on but has no alternative and therefore just accepts the situation. The 
second is Udhalimu an adjective of the verb dhulumu which literally means taking more than 
agreed upon. It is closer to conning, theft, or deliberate taking more than what two parties 
have agreed on. The concept of exploitation in this context refers to two parties or sides where 
the one who oppresses the other must either be economically or politically stronger than the 
oppressed
6
. The following sections address medical and health related studies conducted in 
Tanzania which can illustrate the concept of exploitation in the said context: 
                                               
6 The explained conceptual understanding of exploitation is based on informal discussion with some members of 
existing research ethics committees in Northern Tanzania in 2010 and the University of Dar es salaam in 2011. 
There is a need to establish further if other community members in non-academic environment can have the 
same views since the words nyanyasa and dhulumu might carry different linguistic explanation and 
pronunciations depending on geographical location. Some extensions might not refer to medical or health related 
research. 
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Study No 1: Homeopathy for Health in Africa 
This study is being conducted in Northern Tanzania by Jeremy Sherr
7
. According to Sherr, the 
study aims at carrying out trials investigating the effectiveness of homeopathy
8
 in treating 
AIDS. He did a similar trial at the Nelson Mandela Hospital in South Africa some years ago. 
The study had three arms: 1) patients with homeopathy without Antiretroviral (ARV) 
treatments, 2) patients with homeopathy and ARV treatments, and 3) patients with ARV 
alone.  
 
The initial year report of this study indicates that Sherr had not yet even received ethical 
clearance and that he was in the process of applying for such clearance
9
. According to 
Tanzanian law any clinical trial must be registered by the TFDA and also approved by the 
NIMR after having gone through the local research ethics committee. In addition, since Sherr 
is not a Tanzanian citizen his study must be approved by the COSTECH before start as well. 
Revelation that the researcher and his associates have been conducting the trial among the 
poor and sick communities without ethical and legal approval makes it questionable at this 
point.  
 
The Traditional and Alternative Medicines Act no 23 of 2002 has a provision for promoting 
homeopathy treatment research (URT 2002), but this does not include studies that are denying 
participants from receiving already established therapies such as ARV. The fact that the 
researcher is documenting that he has added up nutritional projects and established a link with 
the local NGOs namely the Tanzania Rural Education and Development Organization 
(TREDO) and Kilimanjaro AIDS Control Centre (KACA) is plausible. But research 
participants without ARV might be deemed exploited if homeopathy treatment is regarded as 
placebo
10
. Within this context the concepts of unyanyasaji and udhalimu would imply that the 
                                               
7
 In his personal website available at: http://semiskimmed.net/woo/jeremy_sherr_AIDS/two-meetings.html 
accessed on 9 February 2011, Jeremy Sherr explains his two meetings with Tanzanian health professionals and 
his detailed plan which is highly criticized by various leaders as unethical on the same page.  
8 According to the web dictionary available at: http://wordnetweb.princeton.edu/perl/webwn?s=homeopathy 
accessed 14 February 2011, Homeopathy is a method of treating diseases with small amounts of remedies that, in 
large amounts in healthy people, produce symptoms similar to those being treated.  
9 In this one year report, it is clearly stated that “We have written a research proposal and are applying for ethics 
approval from the government” Available at: http://www.homeopathyforhealthinafrica.org/project.php. Accessed 
8 February 2011. 
10 Homeopathy treatment is equated to placebo in the Wikipedia Available at: 
http://en.wikipedia.org/wiki/Homeopathy Accessed 14 February 2011 
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sick participants have no alternative than finding any possible means thought to be of help. At 
the same time researchers take advantage to test their alternative conventional medicine 
strategies. To the other extreme we need further to establish why the study was started 
without ethical and research approval from relevant authorities for almost two years, despite 
an annual web-based published report. 
 
Study No 2: Virodene PO5811 
Towards the end of 2001 the Tanzanian government ordered a deportation of two South 
African researchers who were testing a harmful drug among AIDS patients. The drug, 
Virodene P058 was already banned in many countries like the UK and Germany after it had 
been discovered that it was a derivative of the industrial solvent dimethylformamide (DMF) 
which is a highly toxic substance, with the potential of activating the HIV virus. The 
researchers did not receive any approval from the NIMR until it was revealed that they had 
secretly started their trial in a military hospital called Lugalo and another private clinic owned 
by the former inspector general of the police in the country. The controversy involved 
powerful entities: the military, the pharmaceutical industry and politicians. In the midst of 
authorities, regulations and other strong powers there are patients who unknowingly have 
been given the highly toxic substance believing that they were receiving the right 
medications.  
 
There are at least three concerns with regard to this study: One is whether deportation of 
researchers who purposely tested the toxic drug to sick patients represents enough 
punishment? Second, what are the ethical and legal mechanisms for dealing with unethical 
and dangerous studies that are conducted in restricted environments such as military 
premises? Third, what could be the welfare of those who were on the dose after the study was 
stopped? As a matter of fact, both ethical and legal regulations in the country are ‘silent’ with 
regard to these matters. It seems that researchers were aware of such loop holes and therefore 
got an ample chance of entering into agreement with the military authorities without involving 
the NIMR, TFDA or COSTECH as required. None of these regulatory authorities have any 
provision for sanctions when such situations occur, and the government action for deportation 
was just an alternative which has nothing to do with the unethical study done by the convicts. 
                                               
11 Available at http://www.essentialdrugs.org/edrug/archive/200109/msg00039.php Accessed 9 February 2011 
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The first two questions have to do with the legal mechanisms that are unclear. Perhaps that is 
why it was easy for researchers to conduct an unapproved study in the military hospital. The 
last question can be explained within the context of exploitation in the mentioned two 
meanings where patients had no alternative and therefore the toxic substances were offered to 
them (nyanyasa), and also where they believed to have been receiving the right medication, 
hence missing the right protection and correct treatment (dhulumu). (The Lugalo military 
hospital caters for in and outpatient services among army members and the civilians in the 
surrounding areas). 
 
Study No 3: The Trials of Thomas Butler 
Thomas Butler, an American microbiologist conducted a clinical trial in the Northern East of 
Tanzania to find out the efficacy of a new antibiotic - gentamicin - on the bubonic plague and 
later on to fight bioterrorism in case the germ is used for that purpose in the USA. In addition 
to taking samples from 42 patients who had not consented to participate in the study, the 
Federal Bureau of Investigation (FBI) in the USA accused Butler of possibly misplacing the 
samples thought to be dangerous for the citizens of the USA (Enserink and Malakoff 2003). 
The fact that the researcher administered 30% less of the antibiotic than is recommended 
represents a clear exposure of research participants to unnecessary risks lest they develop 
resistance to that deadly infection (Enserink 2003). And this actually fits both concepts of 
unyanyasaji and udhalimu; oppression, fraud, conning, or oppressing the vulnerable persons 
without alternative. One can imagine an already infected patient receiving a less 
recommended dose from a qualified and trusted doctor who has travelled all that far to bring 
“help”. The following observations are worth noting in the presented case stories: 
 
First, studies conducted among vulnerable participants are being assisted by qualified medical 
and health professional citizens acting as part-time entrepreneurs who consider potential risks 
to participants as more lightly (Lemmens 2004). In the first case Sherr had referred to a 
number of local professionals as collaborative partners. In the second case there is a link 
between researchers, military doctors and the Inspector General of the Tanzania police force 
who is mentioned as the owner of the second trial site, a private hospital in Dar es salaam. In 
the third presented case, the regional medical officer in the trial site is acting as the Principal 
Investigator, leaving Butler as an international consultant and then contorted to be the second 
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author in published results
12
. Powerful structures within the country such as the police, 
politicians and professionals are important in making sure that the welfare of research 
participants is observed as it is supposed to be. Their knowledge and positions are always a 
target for criticism if they take part in unethical studies. 
 
Second, there is a suspected “hidden” agenda in exploitative and unethical studies. Like in the 
presented case stories, an on-going homeopathy treatment trial among an unspecified number 
of participants in the Northern Tanzania is unclear. The published first year report further 
indicates uncoordinated and ambitious mission where the researcher has listed a number of 
other projects such as poultry, education, nutrition, and partnership with local Non-
Governmental Organizations (NGOs) probably extending beyond the trial site or objectives. 
 
Moreover, now we know that the toxic derivative from industrial solvent cannot be acceptable 
for human treatments at any rate, but one can wonder what motivated the researchers to make 
a try while being aware that such trials would put patients in danger of losing their lives. 
Under close assessment one could say that the discovery of the plague bug in Tanzania and 
the interest to conduct research was not to save the Tanzanian population per se. The FBI and 
the Federal authorities in the USA had no interest in finding out what happened to the poor 
research participants who were under-dosed during the trials. In addition, they were not 
interested in knowing how the samples were handled through the FedEx courier when the 
researcher shipped them back to Tanzania (Enserink and Malakoff 2003). There is a need for 
relevant authorities in poor and low income countries to find out the proper safety for 
vulnerable citizens who are enrolled in questionable studies which might put them into risks. 
  
Summary and concluding remarks 
It is quite clear that progress in medical and health related research has resulted in the 
development of innovative curative and preventive measures which are important for the 
welfare of human beings in all parts of the world. Since at some points such research requires 
participation of human beings, there have been a number of both national and international 
regulations and guidelines which are responsible for establishing mechanisms for possible 
consideration of professional conduct that would protect the safety, so that they are not 
                                               
12 Mwengee is the first while Butler is the second author of these research results presented in the Oxford 
Journals in 2006. See “Treatment of Plague with Gentamicin or Doxycycline in a Randomized Clinical Trial in 
Tanzania” at http://cid.oxfordjournals.org/content/42/5/614.abstract  
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subjected to unnecessary harms. This chapter has highlighted and discussed the historical, 
economic and political situation that has shaped ethical and legal mechanisms of regulating 
medical and health related research in Tanzania. Some weaknesses and loopholes have been 
discussed through the analysis of case stories that indicate different forms of exploitation in a 
Tanzanian context.  
 
The ethical and legal mechanisms to regulate research in Tanzania have been characterised by 
a mix and ambiguous, or rather a duplication of responsibilities that has caused inertia and 
thus created a loop hole for violating the rights of vulnerable research participants and 
subjecting them to ethically unjustifiable forms of harm and risks. The most probable reason 
for this could be that penalties for unethical and fraudulent researchers are currently unclear. 
In many instances unethical studies are conducted by foreign researchers who are being 
assisted by local professionals while operating in the same system, by side-lining the 
established authorities. There is a need to revisit existing mechanisms and strengthen them by 
having a strong regulatory authority with full mandate of providing adequate protection for 
vulnerable research participants.  
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CHAPTER FOUR 
ANALYSIS OF THE CONCEPT OF BENEFIT IN CURRENT DECLARATIONS 
Introduction 
This chapter intends to give an analysis on how the concept of benefit in medical and health 
related research ethics is conceived of in different declarations and ethical guidelines. It aims 
specifically at describing how this concept has been expressed or modified in guidelines and 
declarations. Further discussion on the position of benefit for research in poor and low income 
countries in terms of health needs and the “10/90 gap” which refers to the mismatch in global 
spending on health care research between affluent and poor and low income countries, will be 
done to explain how benefit merge fairly or unfairly. The controversy of placebo use in 
research and how other scholars have discussed the concept of benefit will be considered in 
the light of looking at the future role of the Declaration of Helsinki. 
Background to declarations 
The World Medical Association (WMA) provided for the ethical principles in medical 
research involving human participants that was adopted by the 18
th
 WMA general Assembly 
in Helsinki, Finland, (hence Declaration of Helsinki) June 1964. These principles have been 
amended and recorded several times in history since then. Further directives and international 
guidelines for research involving human beings have also been put in place from time to time. 
For instance the Council of International Organisations of Medical Sciences (CIOMS) in 2002 
in collaboration with the World Health Organisation (WHO) developed 21 guidelines for 
biomedical research involving human participants with some emphasis on research in poor 
and low-income countries. The Nuffield Council on Bioethics (NCoB) has issued reports on 
human research and clinical trials in these countries mentioning the need for considering the 
socio-cultural variations in terms of informed consent and the role of Community Advisory 
Boards (CAB’s) and in 2005 the United Nations Education Scientific and Cultural 
Organization (UNESCO) adopted the Universal Declaration of Bioethics and Human Rights 
(UDBHR) which among others, recognizes respect for human dignity and observance of 
human rights in ethical issues raised by advances in science and technology (UNESCO 2005). 
Some of the arising issues in these guidelines have been problems in adaptation and 
implementation of crucial elements that call for attention in medical and health related 
research mostly due to cultural contradictions and a quest for universal understanding of 
current practices as far as benefit and benefit sharing is concerned. Critics of these 
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international guidelines and declarations have stated that such issues have been addressed in 
general terms, and they can be interpreted in different ways. (Marshall 2003; Benatar 2005).  
 
Changes of the concept of benefit in revised declaration of Helsinki 
It is widely recognized that international research could bring benefit to the poor communities 
if deliberate efforts and plans are made in order to share the benefits accrued from research. 
To achieve this there is a need to have clear agreement between researchers, sponsors and the 
host country in which research participants are recruited. Among the controversial issues in 
terms of benefit and benefit sharing in medical and health related research, is the discussion of 
post-trial benefits which have been undergoing change in the latest revision of the Declaration 
of Helsinki and now indicates uncertainty with regard to the availability and affordability of 
successful experimental intervention for poor communities. The earlier version stated: “At the 
conclusion of the study, every patient entered into the study should be assured of access to the 
best proven prophylactic, diagnostic and therapeutic methods identified by the study” 
(Paragraph 30), while the latest version states (paragraph 33) that patients are entitled either 
“to be informed about the outcome of the study and also access …of other appropriate care or 
benefits”, but in this revision such appropriate care or benefit are not clearly specified.  
 
Furthermore, the additional principle 29 of the declaration of Helsinki to include the use of 
placebo or non-treatment in studies where proven preventive, diagnostic or treatment method 
exists is another element that has created a significant change in the concept of benefit in the 
current revision. Appropriate standard of care among research participants has been debated 
over a decade. Most of the arguments are put forward against applications of placebo or no 
treatment using available interventions when testing a new drug. Many documented studies 
have criticized the use of placebo in studies involving HIV / AIDS patients in areas where 
antiretroviral treatments (ART) are established interventions. Denying or withdrawing already 
existing intervention such as ART just as randomizing participants to two different trial drugs 
where one is inferior to the other, has always been seen as both inhuman and morally 
unacceptable (McIntyre, Bagenda et al. 1998; Forster, Emanuel et al. 2001; Macklin 2001; 
Kottow 2002; Solbakk 2004; Malmqvist 2011). Moreover, from a human rights perspective, 
proper treatment is a right all human beings possess and the opposite of it would be construed 
as a criminal offence against humanity.  
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Benefit in terms of global health research and healthcare needs 
For more than a decade the Global Forum for Health Research (GFHR) has subsequently 
reported an estimate of only 10 per cent of the world’s medical and health research resources 
being directed to health problems in poor and low income countries where the remaining 90 
per cent has been located to other preventable health problems (GFHR 1999; GFHR 2000; 
GFHR 2002; GFHR 2004); and so on. The forms of collaborative transnational research to 
correct this, also known as 10/90 gap, has been a strategy throughout the years, leaving away 
complex ethical issues arising out of the interplay between such collaborations and most 
arguably, the global health inequalities in terms of standard of care, post-trial benefits and the 
challenge of acceptable mechanisms of strengthening both research and scientific capacity 
within the host countries which would require a new international moral commitment 
(Benatar and Singer 2000; Benatar and Singer 2010). Underpinning such a commitment, the 
missing hub has been a little observation on issues such as political, social and cultural 
background of the host countries, education needs to research ethics members, relevance of 
the proposed studies in the host countries, balance of benefits and evaluation of if and how the 
study findings will fit into the health care system within the host countries, among others.  
 
Furthermore, International collaborative research activities have posed a number of ethical 
questions for Research Ethics Committees (REC’s) – also known as Institutional Review 
Boards (IRB’s), arising from issues such as data sharing and samples, imbalanced scientific 
development and capacity plus legal ownership and intellectual property rights. Developing a 
balanced mechanism for research collaboration has been seen as a strong barrier, more 
importantly in terms of trust between institutions in poor and low income countries from the 
south, and developed countries in the north. Yet, despite these challenges, research 
participants in poor and low income countries are witnessing and involved in an influx of 
transnational research activities, also called “Multi-country” studies having passed by a weak 
system of ethical reviews within their nations, or having approved by their fellow 
neighbouring countries. The question as to who should be responsible in balancing the on-
going system in order to make a trusted scientific and non – scientific network that would 
clearly address benefits among the vulnerable participants has remained side-lined or rather, 
superficially answered. 
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Future perspective: A way forward 
In order to ensure that international collaborative research meets the needs of participants and 
citizens in poor and low income countries, appropriate models for medical and health related 
research are crucial. Given the voluminous of international guidelines and regulations 
currently available, it is important to develop rigorous and clear procedures under which 
research activities will be done in acceptable ways; especially where some documents such as 
the Declaration of Helsinki and other guidelines seem to conflict with the reality of existing 
situations. It is from this background that Latin America has come up with the Declaration of 
Cordóba about ethics in research involving human beings, which proposes to abandon the 
Declaration of Helsinki and start using the UDBHR instead. Major explanations stem on four 
important issues: First, there are clear indications that the latest revision of Declaration of 
Helsinki will negatively affect the rights, well-being and safety of participants who join in 
studies. Second, acceptance of applying some forms of different standards of care because of 
either methods or other reasons is deemed unethical. Third, proposing the use of placebo 
where there are already established interventions is both unethical and against human rights. 
Fourth, the lack of strong obligations for post-trial benefits to study populations has much to 
do with disrespecting the host community that has accepted to participate in the study in 
question (Garrafa 2008; Garrafa, Solbakk et al. 2010). The need to establish a coalition 
between member states regional wise might be a desirable option in order to see to it that the 
UDBHR is implemented. 
 
Though it is generally acceptable that independent research ethics review committees should 
take a lead in ensuring that appropriate and effective ethical standard are observed in research 
conducted in host countries, this has always been undermined due to limited capacity. In the 
first place, finding out who and how one should be responsible in building such a capacity, 
might be among the desirable ways towards building sustainable shared values and practices 
that are essential in solving medical and health problems of mankind. Having well written 
guidelines, signing declarations or mentioning their existence and putting trust in the actual 
practice are two different perspectives that need bridging. 
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Concluding remark 
This chapter was not a replicate of the Declaration of Helsinki and its several revisions. 
Neither was it a replicate of other guidelines that govern medical and health related research. 
Attempts to give an analysis of the concept of benefit in these guidelines have been made by 
relying different arguments provided by different scholars. Most of arguable criticisms over 
the current revision of the Declaration of Helsinki stem in how the concept of benefit and 
benefit sharing has been expressed and modified or rather, ignored by researchers and 
sponsors plus the controversy of placebo use in research. Further discussion on the position of 
benefit for research in poor and low income countries in terms of health care needs and the 
“10/90 gap” has been discussed in terms of the emerging international research undertakings 
to correct it which have brought up further ethical complexities in terms of governance. The 
suggested way forward is based on the Latin American suggestions expressed in the 
Declaration of Cordóba about ethics in research involving human beings, to abandon the 
declaration of Helsinki and implement the UDBHR with a call to form a regional coalition 
between member states so as to honestly find out a solution of how and who should be 
responsible in building sustainable shared values and practices in order to bridge the gap 
between theory and the right practice towards solving medical and health related problems to 
human beings.  
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